$ACXP

Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Acurx Pharmaceuticals (NASDAQ:ACXP), AlphaTON Capital (NASDAQ:ATON)

Shares of Confluent Inc ( NASDAQ:CFLT ) rose sharply in pre-market trading. Confluent is exploring a sale after attracting acquisition interest from tech firms and private equity investors, according to Reuters. Confluent shares jumped 19.5% to $24.77 in the pre-market trading session.

Original reporting
Benzinga · Avi Kapoor
Published Oct 8, 2025, 8:43 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 8, 2025, 9:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Acurx Pharmaceuticals (NASDAQ:ACXP), AlphaTON Capital (NASDAQ:ATON) — source image
Decision brief

The 30-second read

$ACXPBullishMed
01

Why it matters

The surge in ACXP suggests increased investor interest, possibly due to sector developments or company-specific news, which could lead to short-term trading opportunities.

02

Market read

The news primarily affects the US technology and life sciences sectors, with potential short-term trading implications for related stocks.

03

What to watch

Broader market conditions, overall sector performance, and upcoming earnings reports could significantly influence stock movements beyond the immediate news.

Timing: Immediate to short-term (next 1-3 days)

Background

The article reports a sharp pre-market increase in Confluent Inc shares, driven by acquisition interest, and highlights other stocks moving in pre-market trading.

Company-level read

Ticker impact

$ACXPBullishMedium confidence
Context

High relevance due to recent pre-market trading surge and acquisition interest.

Expected impact

Moderate upward movement expected over the next 1-2 days, approximately 3-5%.

Evidence & confidence

The news highlights a significant pre-market rise driven by acquisition interest, which could lead to short-term gains. However, the overall market sentiment and other factors remain neutral, warranting cautious optimism.

Market effects

Potential positive impact on the Technology and Life Sciences sectors due to acquisition interest and pre-market activity.

Limited; primarily affecting US markets given the focus on NASDAQ-listed stocks.

Low; news pertains mainly to US equities and does not indicate broader global market shifts.

Counterpoint

The pre-market surge in ACXP may be short-lived if acquisition talks do not materialize into a deal, leading to potential reversals.

Key entities

  • Confluent Inc

    A data streaming platform exploring a sale amid acquisition interest.

  • AlphaTON Capital

    A publicly traded company showing a somewhat bullish sentiment.

Related articles

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$RKLBMedAI 8/10

Rocket Lab Now Prime and Bus Supplier in GEO: Viasat Selects Lightning-GEO for Anti-Jam Satellite

Rocket Lab was selected by Viasat to supply the satellite bus for Viasat’s U.S. Space Force anti-jam Protected Tactical SATCOM-Global (PTS-G) Swarm 1 spacecraft, using Rocket Lab’s Lightning-GEO platform. Viasat will integrate, operate, and lead the prime role; Rocket Lab builds the bus. The Swarm 1 delivery order totals about $437.7M across contractors; terms were not disclosed.

$LHXMed

L3Harris ousts CEO Kubasik over conduct violation

L3Harris Technologies said CEO Christopher Kubasik stepped down after a board investigation found misconduct and the company entered a separation agreement. The company did not disclose details, saying the conduct was unrelated to financial reporting or operations. Sam Mehta was named successor. Reuters reported no severance, but he can keep vested options. LHX shares fell.